A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity

Huei Jiun Yang, Meng Chi Yen, Chi Chen Lin, Chiu Mei Lin, Yi Ling Chen, Tzu Yang Weng, Tzu Ting Huang, Chao Liang Wu, Ming Derg Lai

研究成果: Article同行評審

25 引文 斯高帕斯(Scopus)

摘要

Many types of malignant cells have a higher nicotinamide adenine dinucleotide (NAD) turnover rate than normal cells, as well as the ability to escape immune responses. Indoleamine 2,3-dioxygenase (IDO) is reported to be a negative immune regulator. Overexpression of IDO in dendritic cells is observed in tumor-draining lymph nodes. IDO-expressing dendritic cells suppress T-cell activation and promote immune tolerance. The nicotinamide phosphoribosyl transferase (NAMPT) inhibitor APO866 (also called FK866 or WK175) selectively inhibits tumor growth through intracellular NAD depletion. The IDO-specific inhibitor L-1-methyl-tryptophan (L-1MT) activates immune responses and reduces tumor volume in murine tumor models. We combined L-1MT and APO866 treatments and tested their antitumor effects in the murine gastric and bladder tumor models. In immune-competent mice, a combination of APO866 and L-1MT had a better therapeutic effect than did either L-1MT or APO866 alone. The intracellular level of NAD was suppressed by APO866 but not L-1MT. However, an additive inhibitory effect on tumor growth was not observed in tumor-bearing immune-deficient mice. The new strategy of combining a metabolic inhibitor and an immune adjuvant induced a potent therapeutic effect.

原文English
頁(從 - 到)869-876
頁數8
期刊Experimental Biology and Medicine
235
發行號7
DOIs
出版狀態Published - 2010 七月

All Science Journal Classification (ASJC) codes

  • 生物化學、遺傳與分子生物學 (全部)

指紋

深入研究「A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity」主題。共同形成了獨特的指紋。

引用此